Dr. Joseph Stilwill, MD
Hematology & Oncology (Hematology & Oncology Physician)
- Medicare participating
At a glance
- Medical school
- University of Iowa, Rj & L Carver College of Medicine (2002)
- Years since graduation
- 24
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 578
Licensed in Illinois since 2005, according to the Illinois Department of Financial and Professional Regulation. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2002Medical school: University of Iowa, Rj & L Carver College of Medicine
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
KS license 04-35975 -
Hospitalist Physician
IL license 036113915 (first issued 2005; not renewed) -
Internal Medicine Physician
IL license 036113915 (first issued 2005; not renewed)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Centerpoint Medical Center Independence, MO
- Menorah Medical Center Overland PArk, KS
- Overland PArk Reg Med Ctr Overland PArk, KS
- Lee's Summit Medical Center Lees Summit, MO
- Kansas City Orthopaedic Institute Leawood, KS
Medical groups
- Midwest Oncology Associates LLC (22 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 578
- Services billed
- 1,773
- Patients’ average age
- 75
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 712 | 309 |
| Established patient office or other outpatient visit, 20-29 minutes | 502 | 319 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 347 | 108 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 119 | 101 |
| New patient office or other outpatient visit, 30-44 minutes | 60 | 60 |
| Established patient office or other outpatient visit, 40-54 minutes | 34 | 27 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 29 | 27 |
| New patient office or other outpatient visit, 45-59 minutes | 21 | 21 |
| Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | 16 | 16 |
| Telephone medical discussion with physician, 11-20 minutes | 12 | 11 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Anastrozole Other prescribers in Overland PArk, KS | 164 |
| Prednisone Other prescribers in Overland PArk, KS | 80 |
| Hydroxyurea Other prescribers in Overland PArk, KS | 74 |
| Revlimid (lenalidomide) | 67 |
| Eliquis (apixaban) Other prescribers in Overland PArk, KS | 63 |
| Dexamethasone Other prescribers in Overland PArk, KS | 58 |
| Xarelto (rivaroxaban) Other prescribers in Overland PArk, KS | 55 |
| Letrozole Other prescribers in Overland PArk, KS | 54 |
| Tamoxifen Citrate Other prescribers in Overland PArk, KS | 54 |
| Imbruvica (ibrutinib) | 51 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 7 companies reported 20 payments worth $347 in total to this clinician.
| Pfizer Inc. | $189 |
|---|---|
| GlaxoSmithKline, LLC. | $46.37 |
| AbbVie Inc. | $28.16 |
| Daiichi Sankyo Inc. | $27.65 |
| AstraZeneca Pharmaceuticals LP | $24.49 |
| Celgene Corporation | $17.86 |
| Rigel Pharmaceuticals, Inc. | $13.92 |
| Food and Beverage | $347 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 9 industry-funded studies in 2025, from 7 companies. The companies reported $415,055 in research payments for these studies, mostly to the institutions running them.
- Tiragolumab Tecentriq vs Durvalumab in Unresectable Stage III NSCLC
Genentech, Inc. - PhII Placebo Controlled of Tiragolumab and Atezo in NSCLC
Genentech, Inc. - Ribociclib Standard Endocrine therapy in patients with HR HER2 Early BC at High amp Intermediate Risk for Recurrence
Novartis Pharmaceuticals Corporation - A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermedi…
Incyte Corporation - Multicohort Study to Customize Ibrutinib Treatment Regimens for Patients with Previously Untreated Chronic Lymphocytic Leukemia
Janssen Research & Development, LLC - Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast Cancer
Eli Lilly and Company · Active, not recruiting · NCT03155997 - A Phase III, Randomized, Double-blind, Multicenter, Global Study of Rilvegostomig or Pembrolizumab Monotherapy for the First-line Treatment of Patients with PD-L1-high Metastatic Non-small Cell Lung Cancer ARTEMIDE-Lu…
AstraZeneca Pharmaceuticals LP - Phase 3 Study of Sitravatinib Plus Nivolumab vs Docetaxel in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer
Mirati Therapeutics, Inc. · Terminated · NCT03906071 - A Phase III Randomized Multi Center OpenLabel Comparative Global Study to Determine the Efficacy of Durvalumab or Durvalumab and Tremelimumab in Combination With Platinum Based Chemotherapy for First Line Treatment in…
AstraZeneca Pharmaceuticals LP
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.